Clostridium difficile is a toxin-producing bacterium that is a frequent cause of hospital-acquired and antibiotic-associated diarrhea. The incidence and severity of C. difficile infection (CDI) are increasing, in parallel with increases in community-acquired infections, making CDI a major public health problem. Following inoculation, patients may clear C. difficile from their intestinal tract, become asymptomatically colonized, or develop CDI, ranging in severity from mild diarrhea to fulminant colitis and/or death. Older adults are disproportionately affected by CDI, experiencing greater morbidity and mortality. Antibiotics treat CDI, but refractory disease and relapses occur. Major gaps exist in our understanding ofthe host and microbial factors that determine the outcome of human contact with C. difficile. The broad objective of this ERIN CRC is to develop innovative approaches to the diagnosis, prevention, and treatment of CDI based on understanding the molecular mechanisms of disease. The goals of this Proiect are to use genomic information obtained from clinical C. difficile strains, to identify microbial determinants of infection and develop a rapid, high-throughput assay to predict the clinical behavior of individual C. difficile strains. We hypothesize that there is a genomic basis for the different clinical presentations of C. difficile (colonization, mild or severe infection, and relapse) in susceptible hosts.
The Specific Aims of this proposal seek to: (1) Establish a collection of isolates that spans the genetic diversity of C. difficile associated with both asymptomatically colonized adults and those with initial and recurrent infection;(2) Perform a comparative phylogenomic analysis of representative C. difficile isolates obtained from Aim 1;and (3) Develop a high-throughput single nucleotide polymorphism (SNP) typing system for the rapid discrimination and risk-assessment ofC. difficile infection. This project will collect clinicoepidemiological data, biological specimens and C. difficile strains, which will be used in all three major projects of this ERIN.
Clostridium difficile is a common cause of antibiotic-associated and hospital-associated diarrhea. It is an emerging pathogen that is highly transmissible and opportunistic, imposing a significant burden on global health and healthcare resources. The best method to control the spread of CDI is to better understand its pathogenesis. These studies will provide an important foundation for developing more accurate diagnostic, preventive, and therapeutic regimens against this important problem.
|Seekatz, Anna M; Wolfrum, Emily; DeWald, Christopher M et al. (2018) Presence of multiple Clostridium difficile strains at primary infection is associated with development of recurrent disease. Anaerobe :|
|Rao, Krishna; Higgins, Peter D R; Young, Vincent B (2018) An Observational Cohort Study of Clostridium difficile Ribotype 027 and Recurrent Infection. mSphere 3:|
|Seekatz, Anna M; Theriot, Casey M; Rao, Krishna et al. (2018) Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Anaerobe :|
|Ulrich, Robert J; Santhosh, Kavitha; Mogle, Jill A et al. (2017) Is Clostridium difficile infection a risk factor for subsequent bloodstream infection? Anaerobe 48:27-33|
|Chen, Liang; Wilson, Justin E; Koenigsknecht, Mark J et al. (2017) NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth. Nat Immunol 18:541-551|
|Dahl, Jan-Ulrik; Gray, Michael J; Bazopoulou, Daphne et al. (2017) The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation. Nat Microbiol 2:16267|
|McDermott, Andrew J; Falkowski, Nicole R; McDonald, Roderick A et al. (2017) Role of interferon-? and inflammatory monocytes in driving colonic inflammation during acute Clostridium difficile infection in mice. Immunology 150:468-477|
|Rogers, M A M; Aronoff, D M (2016) The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect 22:178.e1-178.e9|
|Seekatz, Anna Maria; Rao, Anna Maria; Santhosh, Kavitha et al. (2016) Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. Genome Med 8:47|
|Theriot, Casey M; Bowman, Alison A; Young, Vincent B (2016) Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine. mSphere 1:|
Showing the most recent 10 out of 87 publications